1 completed, 1 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow ALLN-177: new trials by email Literature Review of ALLN-177 trials Research Report on ALLN-177
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria Reloxaliase, Placebo - Enteric Hyperoxaluria | Phase 3 | Terminated | Allena Pharmaceuticals | 92 | 2019-08-26 | 2022-06-10 |
| Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria ALLN-177, Placebo - Enteric Hyperoxaluria | Phase 3 | Completed | Allena Pharmaceuticals | 115 | 2018-05-21 | 2020-02-27 |
Hyperoxaluria (2) · Kidney Calculi (2)
Canada (2) · France (2) · Germany (2) · Italy (2) · Spain (2) · United Kingdom (2) · United States (2) · Austria (1) · Belgium (1) · Brazil (1) · Croatia (1) · Mexico (1) · Portugal (1) · Romania (1) · Russia (1)
Annamaria Kausz, MD MS (1) · David Clark, MD (1)
2018 (1)